<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01655030</url>
  </required_header>
  <id_info>
    <org_study_id>CR-BD-RCT</org_study_id>
    <nct_id>NCT01655030</nct_id>
  </id_info>
  <brief_title>Creatine Monohydrate as Adjuvant Therapy for Bipolar Depression</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of Creatine Monohydrate as Adjunctive Therapy for Bipolar Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether creatine monohydrate is effective as an&#xD;
      adjuvant treatment for bipolar depression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bipolar Depression is associated with high rates of disability and increased mortality.&#xD;
      Despite its major negative impact, treatment of Bipolar Depression is still controversial and&#xD;
      only partially efficacious, with over half of patients not responding adequately to available&#xD;
      treatment. In this context, the use of drugs that modulate energy metabolism has been&#xD;
      proposed as promising new option as treatment strategies for bipolar depression. The aim of&#xD;
      our proposed study is to perform a 6-week randomized, double-blind, placebo-controlled&#xD;
      clinical trial of creatine monohydrate as an adjuvant treatment for bipolar depression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MADRS (Montgomery-Asberg Depression Rating Scale)</measure>
    <time_frame>6 weeks</time_frame>
    <description>change of score on the Montgomery-Asberg Depression Rating Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HDRS-17 (Hamilton Depression Rating Scale - 17-item version)</measure>
    <time_frame>6 weeks</time_frame>
    <description>change of score on the Hamilton Depression Rating Scale - 17-item version</description>
  </secondary_outcome>
  <other_outcome>
    <measure>CGI (Clinical Global Impressions Scale) - Severity and Improvement</measure>
    <time_frame>6 weeks</time_frame>
    <description>change of score on the Clinical Global Impressions Scale</description>
  </other_outcome>
  <other_outcome>
    <measure>YMRS (Young Mania Rating Scale)</measure>
    <time_frame>6 weeks</time_frame>
    <description>change of score on the Young Mania Rating Scale</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Bipolar I Disorder</condition>
  <condition>Current Episode Depressed</condition>
  <arm_group>
    <arm_group_label>creatine monohydrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6g qd for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6g qd for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>creatine monohydrate</intervention_name>
    <arm_group_label>creatine monohydrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals eligible for the study will be adults aged 18 to 60 years of age who met&#xD;
             DSM-IV criteria assessed by the SCID (Structural Clinical Interview for DSM-IV) for&#xD;
             type I bipolar disorder, current episode depressed.&#xD;
&#xD;
          -  Patients who have scored &gt; 19 on the Montgomery-Asberg Depression Rating Scale (MADRS)&#xD;
             will be included, although more than two weeks of treatment with lithium (serum level&gt;&#xD;
             0.8 mEq / L), valproate (serum levels&gt; 50 mg / L) or quetiapine (300-600mg/dia dose)&#xD;
             or drug combination.&#xD;
&#xD;
          -  Antipsychotics, anticonvulsants, benzodiazepines, and thyroid supplementation will be&#xD;
             allowed if the dose has remained stable over the past two weeks.&#xD;
&#xD;
          -  Antidepressants will be allowed if the dosage has remained stable for 4 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with substance abuse within 2 weeks before inclusion or substance dependence&#xD;
             up to 2 months will not be included.&#xD;
&#xD;
          -  Other exclusion criteria will be:&#xD;
&#xD;
               -  diagnosis of schizophrenia,&#xD;
&#xD;
               -  dementia,&#xD;
&#xD;
               -  delirium,&#xD;
&#xD;
               -  epilepsy,&#xD;
&#xD;
               -  mental retardation,&#xD;
&#xD;
               -  clinically unstable medical illnesses,&#xD;
&#xD;
               -  preexisting renal disease,&#xD;
&#xD;
               -  history of hypersensibility to creatine.&#xD;
&#xD;
          -  Not included are individuals at high risk for suicidal or homicidal behavior or&#xD;
             self-mutilation will not be included.&#xD;
&#xD;
          -  Women with gestational potential can only be included if they are using reliable&#xD;
             contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beny Lafer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bipolar Disorder Research Program, Coordinator, IPq-HC-FMUSP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ricardo Toniolo, MD</last_name>
    <phone>55 11 26617928</phone>
    <email>ricardotoniolo.md@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Psychiatry - HC-FMUSP</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01060-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 29, 2012</study_first_submitted>
  <study_first_submitted_qc>July 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2012</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Ricardo Alexandre Toniolo</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

